Skip to Content
Merck
All Photos(3)

Key Documents

A9010

Sigma-Aldrich

Ethyl arachidate

≥99%

Synonym(s):

Ethyl eicosanoate, Ethyl ester of eicosanoic acid, Arachidic acid ethyl ester

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H44O2
CAS Number:
Molecular Weight:
340.58
MDL number:
UNSPSC Code:
12352211
PubChem Substance ID:
NACRES:
NA.25

biological source

synthetic (organic)

Assay

≥99%

form

solid

functional group

ester

lipid type

omega FAs

shipped in

ambient

storage temp.

−20°C

SMILES string

CCCCCCCCCCCCCCCCCCCC(=O)OCC

InChI

1S/C22H44O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h3-21H2,1-2H3

InChI key

YBKSMWBLSBAFBQ-UHFFFAOYSA-N

Related Categories

Application


  • Optimizing the Design of Blood-Brain Barrier-Penetrating Polymer-Lipid-Hybrid Nanoparticles for Delivering Anticancer Drugs to Glioblastoma.: This study explores the development of nanoparticles that can cross the blood-brain barrier to deliver anticancer drugs directly to glioblastoma, utilizing ethyl arachidate in their composition to enhance drug encapsulation and targeting (Ahmed et al., 2021).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Samara R Alves Rico et al.
Nanoscale, 9(30), 10701-10714 (2017-07-06)
A unique class of diruthenium(ii,iii) metallodrugs containing non-steroidal anti-inflammatory drug (NSAID), Ru
Tian Zhang et al.
Advanced healthcare materials, 8(18), e1900543-e1900543 (2019-07-28)
Patients with brain metastases of triple negative breast cancer (TNBC) have a poor prognosis owing to the lack of targeted therapies, the aggressive nature of TNBC, and the presence of the blood-brain barrier (BBB) that blocks penetration of most drugs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service